LSTA FY2024 EPS Boosted by Brookline Capital Management

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Equities research analysts at Brookline Capital Management lifted their FY2024 earnings estimates for Lisata Therapeutics in a research note issued on Wednesday, October 30th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will earn ($2.81) per share for the year, up from their previous forecast of ($2.95). The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.97) per share. Brookline Capital Management also issued estimates for Lisata Therapeutics’ FY2025 earnings at ($2.88) EPS.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.14. During the same quarter in the prior year, the business earned ($0.50) earnings per share.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Lisata Therapeutics in a research report on Wednesday, September 18th.

Lisata Therapeutics Stock Performance

NASDAQ:LSTA opened at $3.16 on Friday. Lisata Therapeutics has a 52 week low of $2.05 and a 52 week high of $3.83. The firm has a market cap of $26.29 million, a price-to-earnings ratio of -1.23 and a beta of 1.21. The firm’s 50-day simple moving average is $2.96 and its 200 day simple moving average is $3.08.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,336 shares of the company’s stock after buying an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. 8.94% of the stock is owned by hedge funds and other institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.